Young-Onset vs Late-Onset Parkinson Disease: A Comparative Review of Clinical Features, Neuropathology, and Genetic Underpinnings

https://doi.org/10.66715/jsccr/2026.v3.i4.4045 Original Research | 2026 | Volume 3 | Issue 4 | Page 40-45

1. Akash sarkar, MD candidate, C.NEURO ( London, uk) , FELLOW RESEARCHER (AIPU) , GENERAL MEDICINE DEPARTMENT, BASHKIR STATE MEDICAL UNIVERSITY UFA RUSSIA University: BASHKIR STATE MEDICAL UNIVERSITY, ORCID ID:0009-0008-2834-1727

2. Dr. Musharapov Denis Razikovich, Professor, MD, PhD, Department of Surgery, Bashkir State Medical University, Ufa, Russia

Young-Onset vs Late-Onset Parkinson Disease: A Comparative Review of Clinical Features, Ne.

Download • 615KB

Corresponding Author:-

Akash sarkar, MD candidate, C.NEURO ( London, uk) ,

FELLOW RESEARCHER (AIPU) ,

GENERAL MEDICINE DEPARTMENT,

BASHKIR STATE MEDICAL UNIVERSITY UFA RUSSIA

University: BASHKIR STATE MEDICAL UNIVERSITY ,

Email ID: akashsarkar20060@gmail.com

ORCID ID:0009-0008-2834-1727

ABSTRACT

BACKGROUND: Parkinson disease (PD) is traditionally viewed as an age-related neurodegenerative disorder; however, clinical and biological heterogeneity significantly influences disease progression. The distinction between young-onset Parkinson disease (YOPD, typically defined as onset ≤50 years) and late-onset Parkinson disease (LOPD, onset >50 years) remains a critical area of investigation for precision medicine.

OBJECTIVE: This review provides a comparative analysis of the clinical, neuropathological, and genetic differences between YOPD and LOPD to elucidate distinct pathophysiological trajectories.

METHODS: A comprehensive synthesis of current literature was conducted, focusing on motor and non-motor phenotypic presentations, rates of disease progression, neuropathological findings, and the prevalence of causative genetic mutations.

RESULTS: Clinical evidence indicates that YOPD patients exhibit a more slowly progressive motor phenotype, characterized by a higher prevalence of early-onset dystonia and levodopa-induced dyskinesias. Conversely, LOPD is associated with faster motor decline, increased risk of early cognitive impairment, and a higher burden of nonmotor symptoms, including autonomic dysfunction and sleep disorders. Neuropathologically, YOPD cases often demonstrate a less extensive α-synuclein (Lewy body) pathology in the brainstem compared to LOPD. Genetically, YOPD shows a substantially higher frequency of monogenic variants ( PRKN, PINK1, DJ-1) compared to the complex, polygenic, or idiopathic architecture typical of LOPD, which is more frequently linked to GBA or LRRK2 risk alleles. CONCLUSION: The dichotomy between YOPD and LOPD is driven by fundamental differences in genetic architecture and molecular pathology, rather than just age of onset. YOPD represents a more distinct genetic subentity with a protracted course, whereas LOPD appears to be a multi-factorial disorder characterized by accelerated neurodegeneration. Recognizing these distinct profiles is essential for refining prognosis, optimizing symptomatic management, and designing targeted clinical trials that account for the diverse etiology of Parkinsonism.